Lapatanib: Oncolytic dual EGFR and erbB-2 inhibitor

Drugs of the Future

Volumn 30, Issue 12, 2005, Pages 1225-1239

  Boyd, B ^a   Bozzo, J ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ARRY 334543; BMS 599626; CAPECITABINE; CETUXIMAB; CP 724714; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERTUMAXOMAB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GENISTEIN; HKI 272; IMC 11F8; INCB 7839; IRINOTECAN; LAPATINIB; LETROZOLE; MATUZUMAB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PELITINIB; PERTUZUMAB; TRASTUZUMAB; TYKERB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; XL 647;

ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; BLADDER CANCER; BLOOD TOXICITY; BREAST METASTASIS; CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CLINICAL TRIAL; DRUG POTENCY; DRUG SYNTHESIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; KIDNEY CANCER; LUNG CANCER; MITOGENESIS; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PROTEIN EXPRESSION; RASH; SIGNAL TRANSDUCTION; STOMACH CANCER; WEIGHT REDUCTION;

EID: 33645122665     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.12.946811     Document Type: Article

References (81)

1. Carter, M.C., Cockerill, G.S., Guntrip, S.B., Lackey, K.E., Smith, K.J. (GlaxoSmithKline plc). Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. EP 1047694, EP 1460072, JP 2002500225, US 2002147205, US 2003176451, US 6713485, US 6727256, WO 1999035146.
2. van der Geer, P., Hunter, T., Lindberg, R.A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994, 10: 251-337.
3. Robertson, S.C., Tynan, J., Donoghue, D.J. RTK mutations and human syndromes: When good receptors turn bad. Trends Genet 2000, 16: 368.
4. Takahashi, M., Hayashi, K., Yoshida, K. et al. Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation 2003, 108: 2524-9.
5. Wells, A. EGF receptor. Int J Biochem Cell Biol 1999, 31: 637-43.
6. Fry, D.W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors. Pharmacol Ther 1999, 82: 207-18.
7. Barnes, C.J., Kumar, R. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. Cancer Metastasis Rev 2003, 22: 301-7.
8. Draper, B.K., Komurasaki, T., Davidson, M.K., Nanney, L.B. Epiregulin is more potent than EGF or TGFα in promoting in vitro wound closure due to enhanced ERK/MAPK activation. J Cell Biochem 2003, 89: 1126-37.
9. Heldin, C.H. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80: 213-23.
10. Amundadottir, L.T., Leder, P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998, 16: 737-46.
11. Frey, M.R., Golovin, A., Polk, D.B. Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling. J Biol Chem 2004, 279: 44513-21.
12. Thomas, S.M., Coppelli, F.M., Wells, A., Gooding, W.E., Song, J., Kassis, J., Drenning, S.D., Grandis, J.R. Epidermal growth factor receptor-stimulated activation of phospholipase Cγ-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 2003, 63: 5629-35.
13. Okano, J., Gaslightwala, I., Birnbaum, M.J., Rustgi, A.K., Nakagawa, H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 2000, 275: 30934-42.
14. Dowlati, A., Nethery, D., Kern, J.A. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 2004, 3: 459-63.
15. Trisciuoglio, D., Iervolino, A., Zupi, G., Del Bufalo, D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 2005, 16: 4153-62.
16. Garrett, T.P., McKern, N.M., Lou, M. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003, 11: 495-505.
17. Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19: 183-232.
18. Rubin Grandis, J., Zeng, Q., Tweardy, D.J. Retinoic acid normalizes the increased gene transcription rate of TGF-α and EGFR in head and neck cancer cell lines. Nat Med 1996, 2: 237-40.
19. Schober, R., Bilzer, T., Waha, A. et al. The epidermal growth factor receptor in glioblastoma: Genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 1995, 14: 169-74.
20. Fallon, K.B., Havlioglu, N., Hamilton, L.H., Cheng, T.P., Carroll, S.L. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line. J Neuro-Oncol 2004, 66: 273-84.
21. Kolibaba, K.S., Druker, B.J. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997, 1333: F217-8.
22. Iihara, K., Shiozaki, H., Tahara, H. et al. Prognostic significance of transforming growth factor-α in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 1993, 71: 2902-9.
23. Nicholson, K.M., Streuli, C.H., Anderson, N.G. Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines. Breast Cancer Res Treat 2003, 81: 117-28.
24. Anderson, N.G., Ahmad, T., Chan, K., Dobson, R., Bundred, N.J. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001, 94: 774-82.
25. Lackey, K.E., Affleck, K., Allen, P. et al. The discovery of a new anti-cancer agent GW2016: A potent, dual EGFR/ErbB-2 tyrosine kinase inhibitor. Proc Am Assoc Cancer Res (AACR) 2001, 42: Abst 4582.
26. Mullin, R.J. Discovery and profile of GW572016, a dual reversible EGFR/ErbB-2 tyrosine kinase inhibitor. 226th ACS Natl Meet (Sept 7-11, New York) 2003, Abst MEDI 11.
27. ClinicalTrials.gov. NCT00225758, NCT00158782, NCT00214409, NCT00103129, NCT00118157, NCT00239200, NCT00111787, NCT00095563, NCT00095667, NCT00095940, NCT00098605, NCT00098631, NCT00099060, NCT00101036, NCT00107536, NCT00113373, NCT00114283, NCT00105950, NCT00089999, NCT00078572, NCT00246753, NCT00206427, NCT00073528, NCT00251433, NCT00103194, NCT00103324.
28. Wood, E.R. III, McDonald, O.B., Yuan, D.H. Evaluation of potency, selectivity, and kinetics of enzyme inhibition by ErbB receptor tyrosine kinase inhibitors. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd ed): Abst 6187.
29. Rusnak, D.W., Affleck, K., Gilmer, T.M., Jowett, A., Lackey, K., Spector, N., Xia, W. The effects of the novel EGFR/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and transformed cell lines. Proc Am Assoc Cancer Res (AACR) 2001, 42: Abst 4309.
30. Rusnak, D.W., Lackey, K., Affleck, K. et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1: 85-94.
31. Lai, G.-H., Sirica, A.E. Effect of GW572016 on ErbB-2 signaling, cell growth, and apoptosis in rat biliary cancer cells. FASEB J 2003, 17(4, Part 1): Abst 163.10.
32. Mukohara, T., Civiello, G., Johnson, B.E., Janne, P.A. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 2005, 68: 500-10.
33. Baerman, K.M., Caskey, L.S., Dasi, F., Earp, H.S., Calvo, B.F. EGFR/HER2 targeted therapy inhibits growth of pancreatic cancer cells. Gastrointest Cancer Symp (Jan 27-29, Hollywood) 2005, Abst 84.
34. Konecny, G.E., Venkatesan, N., Beryt, M., Finn, R., Slamon, D.J., Lackey, K., Rusnak, D.W., Pegram, M. Therapeutic advantage of a dual tyrosine kinase inhibitor (GW2016) in combination with chemotherapy drugs or trastuzumab against human breast cancer cells with HER2 overexpression. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 4974.
35. Konecny, G., Finn, R., Venkatesan, N., Rusnak, D., Gilmer, T., Berger, M., Chen, J., Slamon, D.J., Pegram, M. The novel dual kinase inhibitor GW572016 is particularly active in HER-2 positive and trastuzumab-conditioned breast cancer cells. 26th Annu San Antonio Breast Cancer Symp (Dec 3-6, San Antonio) 2003, Abst 1010.
36. Witters, L.M., Witkoski, A., Planas-Silva, M., Berger, M., Lipton, A. Inhibition of growth of human breast cancer cell lines with the combination of an EGFR/HER-2/neu tyrosine kinase inhibitor and a Bcl-2 inhibitor. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 1694.
37. Xia, W., Gerard, C.M., Liu, L., Baudson, N.M., Ory, T.L., Spector, N. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005, 24: 6213-21.
38. Spector, N., Liu, L., Gerard, C., Baudson, P., Ory, T., Ho, P., Xia, W. Combining lapatinib (GW572016) with anti-erbB2 anti-bodies elicits synergistic apoptotic effects in erbB2 overexpressing breast cancer cells. 41st Annu Meet Am Soc Clin Oncol (May 13-17, Orlando) 2005, Abst 557.
39. Xia, W., Liu, L., Ho, P., Spector, N.L. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3, yet remains sensitive to the ErbB1-ErbB2 kinase inhibitor GW572016. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 189.
40. Zhou, H., Kim, Y.-S., Peletier, A., McCall, W., Earp, H.S., Sartor, C.I. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004, 58 344-52.
41. Kim, Y.-S., Zhou, H., Earp, H.S., Sartor, C.I. Studies of signaling pathways associated with radiosensitization of EGFR over-expressing breast cancer cells by the dual EGFR/HER2 inhibitor, GW572016. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst A98.
42. Grana, T.M., Sartor, C.I., Cox, A.D. Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res 2003, 63: 7807-14.
43. Tansik, R.L., Singer, S.C., Knapp, S.L., Rhodes, N., Gilmer, T.M., Dev, I.K. Synergistic induction of apoptosis between GW570216 and inhibitors of phosphatidylinositol 3-kinase/AKT pathway. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 4661.
44. McHugh, L.A., Griffiths, T.R.L., Kriajevska, M., Mellon, J.K. Dual ErbB1/ErbB2 tyrosine kinase inhibition by GW572016 (lapatinib) - A potential adjunct to systemic chemotherapy in bladder cancer. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 1037.
45. McHugh, L.A., Griffiths, T.R., Colquhoun, A.J., Kriajevska, M., Mellon, J.K. GW572016, a dual tyrosine kinase inhibitor, blocks activation of ErbB1 and ErbB2 in a bladder cancer cell line. J Urol 2004, 171(4, Suppl.): Abst 708.
46. McHugh, L.A., Griffiths, T.R., Colquhoun, A.J., Kriajevska, M., Mellon, J.K. GW572016, a dual tyrosine kinase inhibitor, blocks activation of ErbB1 and ErbB2 in a bladder cancer cell line. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 4398.
47. Xia, W., Mullin, R., Keith, B., Rusnak, D., Rhodes, N., Gilmer, T., Lackey, K., Knight, B., Lucas, S., Spector, N. Effect of GW2016, a dual inhibitor of erbB-2 and EGFR tyrosine receptor kinases, on EGF induced receptor tyrosine autophosphorylation state and downstream signaling pathway. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abst 570.
48. Xia, W., Mullin, R., Keith, B. et al. GW2016, a dual inhibitor of ErbB-2 and EGFR tyrosine kinases: Effects on receptor tyrosine autophosphorylation, downstream signaling intermediaries, and in vivo anti-tumor activity. Proc Am Assoc Cancer Res (AACR) 2001, 42: Abst 3635.
49. Xia, W., Mullin, R.J., Keith, B.R., Liu, L.-H., Ma, H., Rusnak, D.W., Owens, G., Alligood, K.J., Spector, N.L. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21: 6255-63.
50. Mullin, R.J., Murray, D.M., Onori, J., Keith, B.R. Xenograft response to combination therapy with the ErbB1-ErbB2 tyrosine kinase inhibitor GW572016. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3823.
51. Mullin, R.J., Keith, B.R., Murray, D.M., Onori, J. Combination therapy with the dual EGFR-ERBB-2 tyrosine kinase inhibitor GW572016. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 970.
52. Chu, I., Blackwell, K., Chen, S., Slingerland, J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005, 65: 18-25.
53. Blackwell, K., Spector, N., Snyder, S., Marks, J., Xia, W., Liu, L.-H., Broadwater, G., McDonnell, D., Dewhirst, M. GW572016, a novel dual EGFR/Her-2 small molecule, tyrosine kinase inhibitor induces regression and significant growth delay in tamoxifen-resistant, MCF-7 derived tumors. Breast Cancer Res Treat 2002, 76(Suppl. 1): Abst 520.
54. Mullin, R.J., Alligood, K.J., Allen, P.P., Crosby, R.M., Keith, B.R., Lackey, K., Gilmer, T.M., Griffin, R.J., Murray, D.M., Tadepalli, S.M. Antitumor activity of GW2016 in the EGFR positive human head and neck cancer xenograft, HN5. Proc Am Assoc Cancer Res (AACR) 2001, 42: Abst 4579.
55. Keith, B.R., Allen, P.P., Alligood, K.J., Crosby, R.M., Lackey, K., Gilmer, T.M., Mullin, R.J. Anti-tumor activity of GW2016 in the ErbB-2 positive human breast cancer xenograft, BT474. Proc Am Assoc Cancer Res (AACR) 2001, 42: Abst 4308.
56. Clark, K.J., Keith, B.R., Alligood, K., Moseley, C.L., Gilmer, T.M., Mullin, R.J. Pharmacokinetics and pharmacodynamics of GW572016 following oral administration to female BT474-bearing CB-17 SCID mice. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 10-14, Toronto) 2002, Abst W5286.
57. Bence, A.K., Anderson, E.B., Halepota, M.A. et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005, 23: 39-49.
58. DeSimone, P.A., Bence, A.K., Anderson, E.B. et al. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc Am Soc Clin Oncol (ASCO) 2002, 21(Pt. 2): Abst 375.
59. Adams, V.R., Bence, A.K., Anderson, E.B. et al. A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects. Proc Am Soc Clin Oncol (ASCO) 2002, 21(Pt. 2): Abst 374.
60. Smith, D., Koch, K., Lee, D., Mangum, S., Stead, A., Versola, M., DeBerardinis, T., Burris, H., Jones, S., Spector, N. The effect of food on the pharmacokinetics of GW572016. Eur J Cancer Suppl 2003, 1(Suppl. 5): Abst 558.
61. Koch, K., Lee, D., Jones, S., Stead, A., Versola, M., Burris, H., Wilding, G., Taylor, C., Spector, N., Smith, D. Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients. Eur J Cancer Suppl 2003, 1(Suppl. 5): Abst 559.
62. Storniolo, A., Burris, H., Pegram, M., Overmoyer, B., Miller, K., Jones, S., Silverman, P., Paul, E., Loftiss, J., Pandite, L. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. 41st Annu Meet Am Soc Clin Oncol (May 13-17, Orlando) 2005, Abst 559.
63. Burris H.A. III, Storniolo, A.M., Overmoyer, E.A. et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. 27th Annu San Antonio Breast Cancer Symp (Dec 8-11, San Antonio) 2004, Abst 3043.
64. Burris, H.A., Taylor, C., Jones, S., Pandite, L., Smith, D.A., Versola, M., Stead, A., Whitehead, B., Spector, N., Wilding, G. A phase I study of GW572016 in patients with solid tumors. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 994.
65. Burris H.A. III, Hurwitz, H.I., Dees, E.G. et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23: 5305-13.
66. Spector, N., Raefsky, E., Hurwitz, H., Hensing, T., Dowlati, A., Dees, C., O'Neil, B., Smith, D.A., Mangum, S., Burris, H.A. Safety, clincal efficacy, and biological assessments from EGF10004: A randomized phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 772.
67. Burris, H.A., Hurwitz, H., Dees, C. et al. EGF10004: A randomized, multicenter phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor, GW572016. 26th Annu San Antonio Breast Cancer Symp (Dec 3-6, San Antonio) 2003, Abst 39.
68. De Bono, J.S., Schwartz, G., Monroe, P., Beeram, M., Hammond, L., Smith, D., Loftiss, J., Stead, A., Pandite, L., Rowinsky, E.K. Phase I and pharmacokinetic (PK) study of oral GW572016, a potent reversible dual inhibitor of both erbB1 and erbB2 tyrosine kinase (TK), administered in combination with capecitabine. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 901.
69. Mita, M.M., Chu, Q.S., De Bono, J. et al. A phase I and pharmacokinetics (PK) study of the safety and tolerability of the dual EGFR1/ErbB2 tyrosine kinase (TK) inhibitor GW572016 (GW) in combination with capecitabine (C) in patients with advanced solid malignancies. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst A126.
70. Chu, Q., Goldstein, N., Murray, N., Rowinsky, E., Cianfrocca, M., Gale, M., Ho, P., Paul, E., Loftiss, J., Pandite, L. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. 41st Annu Meet Am Soc Clin Oncol (May 13-17, Orlando) 2005, Abst 3001.
71. Chu, Q., Cianfrocca, M.E., Murray, N. et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. 27th Annu San Antonio Breast Cancer Symp (Dec 8-11, San Antonio) 2004, Abst 6044.
72. Jones, S.F., Burris, H.A., Willcutt, N.T., Dickson, N.R., Raefsky, E.L., Greco, A., Versola, M.J., Smith, D.A., Pandite, L.N. A phase I dose escalation study of the dual kinase inhibitor GW572016 in combination with paclitaxel. 26th Annu San Antonio Breast Cancer Symp (Dec 3-6, San Antonio) 2003, Abst 349.
73. Jones, S.F., Burris, H.A., Yardley, D.A. et al. Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. 27th Annu San Antonio Breast Cancer Symp (Dec 8-11, San Antonio) 2004, Abst 1069.
74. Midgley, R., Flaherty, K.T., Haller, D.G., Versola, M.J., Smith, D.A., Koch, K.M., Pandite, L., Kerr, D.J., O'Dwyer, P.J., Middleton, M.R. Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV). 41st Annu Meet Am Soc Clin Oncol (May 13-17, Orlando) 2005, Abst 3086.
75. Blackwell, K., Kaplan, E.H., Franco, S.X., Marcom, P.K., Maleski, J., Sorensen, M., Berger, M.S. A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens. Ann Oncol 2004, 15(Suppl. 3): Abst 103O.
76. Burstein, H., Storniolo, A.M., Franco, S., Salazar, V.M., Sorensen, M.J., Stein, S.H. A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol 2004, 15(Suppl. 3):Abst 104O.
77. Belanger, M., Jones, C.M., Germond, C., Berger, M.S. A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU in combination with irinotecan and/or oxaliplatin. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 978.
78. Fields, A.L., Rinaldi, D.A., Henderson, C.A., Germond, C.J., Chu, L., Brill, K.J., Leopold, L.H., Berger, M.S. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. 41st Annu Meet Am Soc Clin Oncol (May 13-17, Orlando) 2005, Abst 3583.
79. Grimm, M.-O., Machiels, J.-P., Wülfing, C., Richel, D., Treiber, U., de Groot, M., Beuzeboc, P., Farrell, J., Colman, J., El-Hariry, I. A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. 3rd Int Symp Target Anticancer Ther (March 3-5, Amsterdam) 2005, Abst P.506.
80. Wülfing, C., Machiels, J.-P., Richel, D., Grimm, M.-O., Treiber, U., de Groot, M., Beuzeboc, P., Farrell, J., Colman, J., El-Hariry, I. EGF20003: A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Final analysis. Ann Oncol 2004, 15(Suppl. 3): Abst 416O.
81. Gomez, H.L., Chavez, M.A., Doval, D.C., Chow, L.W., Wood, B.A., Berger, M.S., Sledge, G.W. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. 41st Annu Meet Am Soc Clin Oncol (May 13-17, Orlando) 2005, Abst 3046.